Published in J Med Genet on December 01, 1999
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer (2004) 1.43
Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women. Br J Cancer (2002) 1.23
Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer (2002) 1.11
Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. Br J Cancer (2004) 1.04
A Counselling Model for BRCA1/2 Genetic Susceptibility Testing. Hered Cancer Clin Pract (2004) 0.87
Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain. Fam Cancer (2010) 0.83
The impact of familial environment on depression scores after genetic testing for cancer susceptibility. Clin Genet (2008) 0.81
Is genetic counseling a stressful event? Acta Oncol (2011) 0.79
Identification of cognitive profiles among women considering BRCA1/2 testing through the utilisation of cluster analytic techniques. Psychol Health (2011) 0.78
An extended family suddenly confronted with a life-threatening hereditary arrhythmia. Neth Heart J (2005) 0.75
Cancers related to genetic mutations: important psychosocial issues for Canadian family physicians. Can Fam Physician (2006) 0.75
Anxiety and depression symptoms among women attending group-based patient education courses for hereditary breast and ovarian cancer. Hered Cancer Clin Pract (2017) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Impact of Event Scale: a measure of subjective stress. Psychosom Med (1979) 21.82
Identification of the breast cancer susceptibility gene BRCA2. Nature (1996) 17.14
Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol (1985) 9.79
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med (1997) 6.73
Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst (1992) 5.51
The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry (1976) 5.12
Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry (1993) 4.98
Anxiety and depression in patients with chest pain referred for exercise testing. Lancet (1985) 2.85
Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet (1995) 1.95
Prediction of psychological functioning one year after the predictive test for Huntington's disease and impact of the test result on reproductive decision making. J Med Genet (1996) 1.84
Younger women at increased risk for breast cancer: perceived risk, psychological well-being, and surveillance behavior. J Natl Cancer Inst Monogr (1994) 1.52
BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol (1998) 1.52
The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol (1997) 1.46
Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol (1997) 1.46
A randomized trial of breast cancer risk counseling: interacting effects of counseling, educational level, and coping style. Health Psychol (1996) 1.36
Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program. Am J Med Genet (1993) 1.25
Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. The Rotterdam/Leiden Genetics Workgroup. J Med Genet (1997) 1.15
BRCA1 in the family: a case description of the psychological implications. Am J Med Genet (1997) 1.03
Psychological issues in cancer genetics: current research and future priorities. Patient Educ Couns (1997) 0.91
Personality factors and breast cancer development: a prospective longitudinal study. J Natl Cancer Inst (1996) 0.89
The course of anxiety and depression in patients undergoing coronary artery bypass graft surgery. J Psychosom Res (1998) 0.86
Presymptomatic DNA-testing for Huntington disease in The Netherlands. Birth Defects Orig Artic Ser (1992) 0.83
Emotional control and autonomic arousal in breast cancer patients. J Psychosom Res (1984) 0.83
Rationality, emotional expression and control: psychometric characteristics of a questionnaire for research in psycho-oncology. J Psychosom Res (1993) 0.79
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
The small world of metabolism. Nat Biotechnol (2000) 6.35
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol (1998) 5.15
Micrometastases and survival in stage II colorectal cancer. N Engl J Med (1998) 5.11
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
The PILATUS 1M detector. J Synchrotron Radiat (2006) 4.16
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem (1993) 3.41
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res (1988) 3.31
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Clinical studies on submicroscopic subtelomeric rearrangements: a checklist. J Med Genet (2001) 3.28
Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol (1987) 2.96
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet (2000) 2.84
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
Innovation and robustness in complex regulatory gene networks. Proc Natl Acad Sci U S A (2007) 2.70
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet (2005) 2.65
Rapid subchromosomal localization of cosmids by nonradioactive in situ hybridization. Cytogenet Cell Genet (1990) 2.60
Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet (1989) 2.44
Anticipation in myotonic dystrophy: fact or fiction? Brain (1989) 2.41
A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol (2004) 2.37
High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol (2010) 2.32
Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet (1997) 2.27
In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry (1988) 2.26
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol (2001) 2.25
Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut (1980) 2.24
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
Chronic pain and its impact on quality of life in adolescents and their families. J Pediatr Psychol (2001) 2.15
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med (1997) 2.05
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol (2009) 2.04
[Familial forms of fronto-temporal dementia]. Ned Tijdschr Geneeskd (1995) 2.04
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet (1997) 2.01
The fragile X syndrome. J Med Genet (1998) 2.00
Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 1.99
Ever since Knudson. Trends Genet (2001) 1.96
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Two subsets of human alphoid repetitive DNA show distinct preferential localization in the pericentric regions of chromosomes 13, 18, and 21. Cytogenet Cell Genet (1986) 1.90
A mechanism for increased contractile strength of human pennate muscle in response to strength training: changes in muscle architecture. J Physiol (2001) 1.89
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet (1994) 1.88
High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet (1999) 1.87
Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet (1981) 1.84
How can acute mountain sickness be quantified at moderate altitude? J R Soc Med (1996) 1.84
Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol (1999) 1.81
Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene (1991) 1.81
A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum Mol Genet (1992) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res (2001) 1.78
PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol (2000) 1.77
Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77
Familial aggregation in frontotemporal dementia. Neurology (1998) 1.76
Robustness and evolution: concepts, insights and challenges from a developmental model system. Heredity (Edinb) (2006) 1.75
EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet (1999) 1.70
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Assignment of a second locus for multiple exostoses to the pericentromeric region of chromosome 11. Hum Mol Genet (1994) 1.68
Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet (1993) 1.68
Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 1.68
Detection of chromosome aneuploidy in interphase nuclei from human primary breast tumors using chromosome-specific repetitive DNA probes. Cancer Res (1988) 1.67
Sequence heterogeneity within the human alphoid repetitive DNA family. Nucleic Acids Res (1986) 1.65
DNA ploidy and survival in breast cancer patients. Cytometry (1987) 1.65
Efficacy of Nijmegen Questionnaire in recognition of the hyperventilation syndrome. J Psychosom Res (1985) 1.64
Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer (2000) 1.64
Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am J Pathol (1991) 1.63
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer (2009) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Basic research and 12 years of clinical experience in computer-assisted navigation technology: a review. Int J Oral Maxillofac Surg (2005) 1.59